Medication Guide App

Advaxis to Present at the 6th Annual Spring Growth Stock Conference

Event Hosted By Security Research Associates, Inc.

The Omni Hotel, San Francisco, CA | Tuesday, April 6, 2010

NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--Mar 25, 2010 - Advaxis, Inc., (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, has been invited to present at the 6th Annual Spring Growth Stock Conference hosted by Security Research Associates, Inc., (SRA). The conference will be held on Tuesday, April 6th at the Omni Hotel in San Francisco, CA.

Conference attendees will include a select group of institutional portfolio managers and analysts, and will feature CEO's and CFO's from some of the fastest growing companies sector.

SRA has also arranged for a webcast of Advaxis' investor presentation that will be given during the conference. To access the lobby page for the webcast, please go to: http://www.wsw.com/webcast/sra10.

About Security Research Associates, Inc.

Security Research Associates, Inc. (SRA) was founded in San Francisco in 1980 and, today, offers investment banking and M&A services as well as institutional brokerage services. A boutique firm by design, SRA works with a select group of portfolio managers from around the country and focuses on technology and life science companies in the micro and small cap arenas. For more information about SRA see our website at www.sracap.com or call (415) 925-0346.

About Advaxis, Inc.

Advaxis is a biotechnology company developing proprietary, live, attenuated Listeria monocytogenes (Listeria) immunotherapeutics that deliver engineered tumor antigens, which stimulate multiple, simultaneous, immunological mechanisms to fight cancer. Today, the Company has nine (9) distinct, cancer-fighting constructs in various stages of development, directly and through strategic collaborations with such recognized sites of excellence as the City of Hope, the Roswell Park Cancer Institute, the National Cancer Institute, the University of Pittsburgh and Cancer Research – UK. The Company's technology was developed by Dr. Yvonne Paterson, professor of microbiology at the University of Pennsylvania and chairperson of Advaxis' scientific advisory board. Please visit the Company's portals: advaxis.com | facebook | twitter | LinkedIn

Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Company's current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.

Contact: Advaxis, Incorporated
Conrad F. Mir, 732-545-1590
Executive Director
Fax: 732-545-1084
mir@advaxis.com
www.advaxis.com

 

Posted: March 2010

View comments

Hide
(web1)